222 results about "Left ventricular size" patented technology

The invention provides an echocardiogram video abstraction method based on a hierarchical space-time attention mechanism, and the method comprises the steps: obtaining an echocardiogram, inputting the echocardiogram into an anatomy and physiological basic model of a key frame recognition task, and obtaining key frame information; inputting the key frame information into a multi-dimensional spatial-temporal feature extraction model to obtain feature information and frequency domain information; fusing the feature information and the frequency domain information; performing key frame enhancement processing on the fusion information by adopting an SE channel attention mechanism to obtain key frame anatomical feature expression; processing the key frame anatomical feature expression by adopting a key frame backtracking strategy and a classification network to obtain a key frame identification classification result; performing left ventricle segmentation on the classified image by adopting an improved U-Net left ventricle region segmentation network; estimating the area and volume of the left ventricle based on a segmentation result; fusing the estimated left ventricular area and volume by adopting a hierarchical attention mechanism and a cross-layer information fusion strategy to obtain a ventricular volume result; according to the method, through abstract extraction of the key information of the ultrasonic cardiac video, the clinical practicability of intelligent screening and auxiliary diagnosis of cardiovascular diseases based on ultrasonic is improved.

The invention provides a left heart data analysis method and system based on image segmentation, and relates to the technical field of medical image processing. Comprising the following steps: acquiring cardiac ultrasound image data and preprocessing; performing image segmentation on the preprocessed image data to obtain a segmentation result including a left ventricle, a left ventricular wall and a left atrium; searching a boundary line of the left ventricle and the left atrium, selecting two boundary points corresponding to the minimum and maximum abscissas in the boundary line as left and right mitral valve ring points respectively, and establishing a long axis based on the mitral valve ring midpoint and the cardiac apex point; modeling the ventricle into a structure formed by superposing a plurality of discs along the long axis direction, and obtaining the diameter of the corresponding disc; based on the obtained diameters of the corresponding discs, the left ventricular volumes in the diastolic period and the systolic period are calculated respectively, and the left ventricular ejection fraction is calculated. According to the method, image segmentation and geometric modeling are fused to achieve accurate calculation of the cardiac ejection fraction, meanwhile, the accuracy of cardiac structure image segmentation is improved, and an interpretable ejection fraction estimation process is achieved.

The exemplified methods and systems facilitate the quantification of cardiac cycle-variability as a metric of signal quality of an acquired signal data set and the rejection, based on that quantification, of said acquired signal data set from one or more subsequent analyses that can predict and / or estimate a metric associated with the presence, non-presence, severity, and / or localization of abnormal cardiovascular conditions or disease, including, for example, but not limited to, coronary artery disease, abnormal left ventricular end-diastolic pressure disease (LVEDP), pulmonary hypertension and subcategories thereof, heart failure (HF), among others as discussed herein. The quantification of levels of cycle-variability assessed noise such as skeletal-muscle-related-signal contamination and muscle-artifact-noise contamination, and other asynchronous-noise contamination in an acquired signal can be subsequently used for the automated rejection of such asynchronous noise from measurements of biophysical signals.

The invention provides application of a monascus composition in preparation of a medicine for preventing and / or treating coronary microcirculation disturbance. The monascus composition comprises one or more of cortex mori, ramulus mori and folium mori, monascus and radix puerariae. When the composition containing the red yeast rice is applied to preparation of the medicine for preventing and / or controlling coronary microcirculation disturbance, the abnormal microvascular structure can be improved (myocardial microvascular density MVD is increased, edema around microvessels is relieved, the lumen stenosis phenomenon is improved, and the endothelial cell condition is good); 2) microvascular occlusion is improved (pathologic results show that microvascular contents are reduced); (3) the abnormal vasodilatation and contraction function of the microvessels is improved (NO is increased); 4) improving blood lipid metabolism disorder; and (5) the heart function is improved (the left ventricular ejection fraction LVEF and the left ventricular short axis shortening rate LVFS are improved, and the left ventricular pressure maximum rising rate LV + dp / dtmax and the left ventricular pressure maximum falling rate LV-dp / dtmax are increased).

The systems, devices, and methods presented herein use a heart pump to obtain measurements of cardiovascular function. The heart pumps described herein can operate in parallel with and unload the heart. The system can quantify the functioning of the native heart by measuring certain parameters / signals such as pressure or motor current, then calculate and display one or more metrics of cardiovascular function. These metrics, such as left ventricular end diastolic pressure (LVEDP), left ventricular pressure, and contractility, provide valuable information to a user regarding a patient's state of heart function and recovery.

A method is provided that includes inserting an inflow cannula of a left ventricular assist device (LVAD) of a LVAD system into a left chamber of a heart of a patient transeptally via a right atrium and a superior vena cava (SVC). An outflow cannula of the LVAD is coupled to a left subclavian artery or a left axillary artery. Other embodiments are also described.

The disclosure deals with methodology and corresponding apparatus / system subject matter for image-based estimation of left ventricular myocardial stiffness. Increased left ventricular myocardial stiffness is a key factor in the development and progression of heart failure. Despite the potential impact on the clinical management of heart failure, there is currently a lack of available techniques to assess left ventricular myocardial stiffness. To address this limitation, a simple protocol is disclosed for processing routine echocardiographic imaging data to estimate left ventricular myocardial stiffness, with protocol specification for patients at risk for heart failure with preserved ejection fraction, for both sensitivity and translational feasibility of the obtained estimates of left ventricular myocardial stiffness.

The application provides a heart valve positioning device, which comprises a first curved structure, a second curved structure, and a third curved structure. The first curved structure forms a spiral curved structure with a first size in a released state. The second curved structure forms a spiral curved structure with a second size in a released state, and the second size is greater than the first size. The second curved structure has a hollow first cavity for the first curved structure to pass through, forming the third curved structure. The distal end of the third curved structure is a free end, and the proximal end is connected with a delivery system. The third curved structure forms a spiral curved structure with a third size in a released state, and the first size is less than the third size and less than or equal to the second size. The embodiment of the application can reduce left ventricular outflow tract obstruction caused by large-scale movement of the anterior leaflet.

The invention discloses a hypertrophic cardiomyopathy (HCM) preoperative planning and operation effect evaluation method based on accurate digital labeling. The method comprises the following steps: performing digital labeling on the thickness of each wall of a left ventricle of a preoperative heart 3D digital model; according to the digital labeling result of the preoperative heart 3D digital model and the normal value of the thickness of the left ventricular wall, a doctor manually depicts the predicted resection range and confirms the predicted retention thickness; measuring the predicted resection volume, the predicted resection area and the left ventricular end diastolic volume after the predicted resection volume is resected; digitally marking the thickness of each wall of the left ventricle of the postoperative heart 3D digital model, and measuring the volume of the corresponding left ventricle in the end diastole; and taking the predicted resection range, the predicted retention thickness, the predicted resection volume, the predicted resection area and the predicted volume as first evaluation data, taking corresponding parameters of the postoperative heart 3D digital model as second evaluation data, and generating an operation evaluation result according to the conformity of the first evaluation data and the second evaluation data.

Methods and systems are disclosed for creating and using a neural network model to estimate a cardiac parameter of a patient, and using the estimated parameter in providing blood pump support to improve patient cardiac performance and heart health. Particular adaptations include adjusting blood pump parameters and determining whether and how to increase or decrease support, or wean the patient from the blood pump altogether. The model is created based on neural network processing of data from a first patient set and includes measured hemodynamic and pump parameters compared to a cardiac parameter measured in situ, for example the left ventricular volume measured by millar (in animals) or inca (in human) catheter. After development of a model based on the first set of patients, the model is applied to a patient in a second set to estimate the cardiac parameter without use of an additional catheter or direct measurement.

A device for regulating blood pressure between a patient's left atrium and right atrium comprises an hourglass-shaped stent comprising a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum, and a drug-eluting biodegradable material that biodegrades over time to release a drug that limits tissue overgrowth. The inventive device also may include a biodegradable material that biodegrades to offset flow changes caused by tissue overgrowth. The inventive device may reduce left atrial pressure and left ventricular end diastolic pressure, and may increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits.

A device for regulating blood pressure between a patient's left atrium and right atrium comprises an hourglass-shaped stent comprising a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum; and a one-way tissue valve coupled to the first flared end region and configured to shunt blood from the left atrium to the right atrium when blood pressure in the left atrium exceeds blood pressure in the right atrium. The inventive devices may reduce left atrial pressure and left ventricular end diastolic pressure, and may increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits. The inventive devices may be used, for example, to treat subjects having heart failure, pulmonary congestion, or myocardial infarction, among other pathologies.

Disclosed are a method for presenting cardiac myocardial strain and an ultrasound imaging apparatus, comprising: acquiring image data of myocardial segments of both left and right ventricles, and processing this data to obtain motion parameters of both left and right ventricular myocardial segments. A composite bull's-eye plot containing left and right ventricular bull's-eye subplots is displayed, wherein the left ventricular bull's-eye subplot comprises multiple left ventricular myocardial regions corresponding to the left ventricular myocardial segments and presenting motion parameters of the left ventricular myocardial segment; and the right ventricular bull's-eye subplot comprises a right ventricular myocardial region corresponding to the right ventricular myocardial segments that exclude some / all shared segments with the left ventricle and presenting motion parameters of the right ventricular myocardial segment. This configuration enables users to observe motion parameters of both ventricular myocardial segments, thereby providing comprehensive understanding of cardiac myocardial strain while enhancing clinical efficiency for doctors.

The invention provides a self-adaptive control method and device for a double-ventricle auxiliary system. The method comprises the steps that target aortic pressure detected by a first pressure sensor, target left ventricular end diastolic pressure detected by a second pressure sensor, target right atrial pressure detected by a third pressure sensor and target pulmonary artery pressure detected by a fourth pressure sensor are obtained; and determining a strategy for adjusting the left ventricular assist device or the right ventricular assist device according to the target left ventricular end diastolic pressure, the target right ventricular pressure and the target pulmonary arterial pressure when the peripheral perfusion of the target user is insufficient or the lung is over-perfused. The pressure sensors are arranged to detect the pressure of the inlets and the outlets of the left ventricular assist device and the right ventricular assist device, whether adverse events such as peripheral insufficiency or pulmonary hyperperfusion occur to a user or not is judged according to the detected pressure, and then the adverse events are relieved or even solved by adjusting the rotating speeds of the left ventricular assist device and the right ventricular assist device. And the safety of the user is greatly improved.

The application discloses a heart valve device and relates to the technical field of artificial heart valves, which comprises an outer valve frame and a valve leaflet assembly connected to the inside of the outer valve frame, and the outer valve frame is a ring-shaped grid frame; the outer valve frame comprises an inflow side grid frame and an outflow side grid frame arranged in sequence from an inflow end to an outflow end, and the inflow side grid frame and the outflow side grid frame form an annular recess for clamping a native valve ring on the outer periphery of the outer valve frame; the outflow side grid frame comprises a plurality of groups of grid support units connected in sequence along the circumferential direction and enclosed into a ring, and the grid support unit comprises an outer convex grid support and an inner concave grid support, and the outer surface of the inner concave grid support is arranged in a concave manner relative to the outer surface of the outer convex grid support. In this way, the anterior leaflet of the original mitral valve can be attached to the inner concave grid support, the extrusion of the outer valve frame on the anterior leaflet is reduced, the anterior leaflet is prevented from being extruded to the left ventricular outflow tract by the outer valve frame, and the outflow area of the left ventricular outflow tract is prevented from being reduced to cause obstruction.

A stabilizer sleeve is disclosed for use with cardiac implantable electronic device leads. The sleeve comprises a tubular body sized to receive the lead and shaped to bias the lead toward a desired anatomical location, thereby reducing migration, dislodgement, and interference with cardiac structures. The sleeve may be introduced with the lead as a unitary assembly or added after lead placement. Various embodiments include a slitted body for expansion, radiopaque markers for visualization, detachable nose-cone tips for guidewire tracking, and antimicrobial coatings. The sleeve may be formed of polymers, alloys, or composite materials, and may include features such as texturing or anchoring projections for tissue engagement. Applications include positioning within a tricuspid valve commissure to minimize regurgitation and stabilizing left ventricular leads within branches of the coronary sinus. The device and methods described provide improved long-term stability and performance of implanted cardiac leads.

The invention discloses a method for measuring the pressure in the heart cavity of a mouse, and relates to the technical field of experimental animal medical detection, and the method comprises the following steps: cutting an incision of about 1cm in the neck of the mouse; placing two sutures below the common carotid artery, and ligating the common carotid artery by using the suture at the distal end; the other section of suture line is placed in the middle of the right common carotid artery, the carotid artery is lifted up, the blood filling condition is observed, an opening is formed in the blood vessel, a pressure volume catheter is inserted, and meanwhile the suture line at the telecentric end is slightly pulled backwards to prevent bleeding; the pressure volume catheter is inserted into the left ventricle through the right common carotid artery, and the left ventricle pressure maximum rising rate and the left ventricle pressure maximum falling rate are collected. By means of the carotid artery approach, serious trauma caused by thoracotomy can be prevented, and the cardiac physiology can be possibly affected by the operation. Therefore, the carotid artery approach is more suitable for a long-time pressure collection experiment.

A cardiopulmonary management system includes a multi-sensor device and a controller. The multi-sensor device includes an elongated body having a first end and a second end, a first electrode disposed at the first end of the body, a second electrode disposed at the second end of the body, an electrical circuitry disposed near a middle of the body, and a sound sensor. The multi-sensor device is configured to be disposed on a skin of a subject and to measure cardiopulmonary parameters from the subject. The controller is configured to derive a score of sound change, heart rate change, thoracic impedance change, respiratory rate change, QRS wavelength change, QT interval change, electromechanical activation time change, and left ventricular systolic time change based on the measured cardiopulmonary parameters. The controller is further configured to control an operation of the system when the derived score is greater than a threshold.

The invention discloses a biomarker combination for predicting PCI postoperative LVR of an STEMI patient and application of the biomarker combination, and belongs to the technical field of biology. The research discovers that in a left ventricular remodeling (LVR) group and a non-left ventricular remodeling group after percutaneous coronary intervention (PCI) of a patient suffering from acute ST segment elevation type myocardial infarction (STEMI), a left ventricular endocardial lower myocardial overall longitudinal strain (GLS internal) value, a lung B-line integral, a serum sFRP5 level and Apelin-13 show significant differences. Through combined prediction analysis, it is found that the GLS internal value, the lung B-line integral, the serum sFRP5 and the Apelin-13 have excellent prediction performance on whether the LVR occurs after the PCI operation of the STEMI patient or not, high-risk groups, suffering from the LVR after the PCI operation, of the STEMI patient can be accurately and efficiently recognized, intervention is conducted as soon as possible, and the life quality of the patient is expected to be improved.

The present application relates to the medical technical field, especially relate to a kind of noninvasive continuous assessment of ejection fraction method, system and storage medium, the method includes: through monitoring device obtains the multiple physiological parameters of the person to be assessed, wherein, multiple physiological parameters include: the stroke volume of the person to be assessed, left ventricular pre-ejection period and pre-ejection period;Then according to formula calculates the ejection fraction of the person to be assessed;Through relevant monitoring device obtains the multiple physiological parameters of the person to be assessed, specifically, stroke volume, left ventricular pre-ejection period and pre-ejection period, then, the ejection fraction of the person to be assessed can be conveniently calculated and obtained according to the formula provided by the present application, since the related parameters for evaluating ejection fraction in the present application can be continuously obtained by noninvasive method, thus the present application provides a kind of noninvasive continuous ejection fraction evaluation method.

The utility model relates to an adult simulation load device for online calibration of an extracorporeal membrane oxygenation system. The system comprises a left ventricular artery system simulation box, a right atrial vein system simulation box, a resistance device, a V-A ECMO treatment mode artery perfusion cannula, a V-V ECMO treatment mode vein perfusion cannula, a vein drainage cannula, a bottom plate, a right atrial vein system simulation box hydraulic monitoring sensor, a left ventricular artery system simulation box hydraulic monitoring sensor and a manual pressure release valve. And a ball valve pressurizing device and a vertical partition plate. The left ventricular artery system simulation box, the resistance device and the right atrial vein system simulation box are sequentially connected through pipelines. The device is simple in structure, convenient and practical to operate and capable of accurately simulating the blood volume of a patient, the pressure difference between a venous system and an arterial system and the resistance of a blood circulation system when an adult patient adopts a V-A ECMO treatment mode and a V-V ECMO treatment mode respectively, and has practical value; calibration data has clinical guiding significance, the measurement accuracy of key parameters of equipment is effectively guaranteed, and clinical risks are reduced.

The application discloses application of pentagalloyl glucose (PGG) in preparation of an anti-doxorubicin cardiotoxicity medicine. The process is as follows: a myocardial cell H9C2 injury model is induced and established by doxorubicin (DOX), and a minimum concentration of the myocardial cell injury induced by DOX is determined. After 20 muM of PGG is added to a treatment group, DOX-induced H9C2 cell apoptosis can be significantly improved. A mouse myocardial injury model is induced and established by DOX, compared with a doxorubicin group, the left ventricular systolic fraction (FS%) and the ejection fraction (EF%) of mice in the doxorubicin+pentagalloyl glucose group are significantly increased, the myocardial fiber structure is improved, cytoplasm vacuolization is reduced, the serum cTnT and BNP levels are reduced, and the ROS level is reduced. It is proved by the above experiments that the pentagalloyl glucose can significantly reduce DOX-induced myocardial toxicity.

The application discloses a patient classification method and device based on magnetic resonance parameters, equipment, medium, the method comprises the following steps: obtaining the target magnetic resonance parameter of the target patient; the target magnetic resonance parameter is selected from a plurality of preset magnetic resonance parameters based on the cardiac resynchronization label of the sample patient and the true result of the occurrence of the preset endpoint event; the target magnetic resonance parameter comprises a myocardial strain parameter, a gadolinium contrast agent delayed enhancement result and a left ventricular torsion parameter; the target classification tree is input into the target patient, and the target patient is classified by using the target classification tree, and the target classification result corresponding to the target patient is obtained; the target classification tree is obtained by extending the preset classification tree based on the cut-off value of each target magnetic resonance parameter and the influence of meeting each cut-off value on cardiac resynchronization; and the target classification result is output. The application can classify patients more accurately.

The invention belongs to the technical field of new application of medicines, and provides application of Zhongwinning in preparation of a medicine for treating ischemic heart disease. In a myocardial ischemia rat model test, Zhongwinning shows that the Zhongwinning can obviously improve the left ventricular ejection fraction and the left ventricular short-axis shortening rate of a myocardial ischemia rat; in addition, the rising and falling rates of the ventricular pressure of the myocardial ischemia rats can be remarkably improved, and it is indicated that Zhongutanin can effectively recover the left ventricular systolic function and can effectively repair myocardial injury caused by myocardial ischemia reperfusion. Therefore, according to the experimental research result of the application, the Zhongwinning has a certain application prospect in treating the ischemic heart disease.

The invention discloses an automatic heart magnetic resonance scanning method and device. The method comprises the following steps: acquiring a cardiac magnetic resonance scanning localization map of a scanned object; according to the scanning positioning map, determining a first target scanning positioning line through a preset deep learning algorithm; according to the first target scanning positioning line, determining a left ventricular short axis section image through a preset deep learning algorithm; according to the left ventricular short-axis section image, determining a second target scanning positioning line and a second target section image corresponding to the second target scanning positioning line through a preset deep learning algorithm; under-sampling and respiratory navigation are adopted, and a heart magnetic resonance image is determined according to the second target scanning positioning line and the second target section image. According to the technical scheme, the scanning positioning image can be automatically positioned through the preset deep learning algorithm, the heart magnetic resonance image is scanned through combination of undersampling and respiratory navigation, and full-automatic positioning and full-automatic scanning in the heart magnetic resonance image scanning process can be achieved.

The application discloses a method for obtaining a left ventricular papillary muscle target section and an ultrasonic evaluation method thereof, which comprises obtaining a standard basic section conforming to a guideline, and then determining a corresponding target section and a two-dimensional ultrasonic probe adjustment mode according to a front-lateral or rear-medial papillary muscle type to be imaged and a current standard basic section. Through taking the probe pose when the standard basic section is obtained as a benchmark, the two-dimensional ultrasonic probe is rotated by a specified angle or is directionally tilted under the premise of maintaining an acoustic window unchanged, so that an image of the target section clearly displaying a specific papillary muscle long axis or short axis shape is obtained; the problem of incomplete papillary muscle imaging and distorted shape caused by the fixed section of the conventional two-dimensional ultrasonic is solved, the target section can be repeatedly and stably obtained, and the integrity and accuracy of the papillary muscle ultrasonic imaging are significantly improved.

In some instances, a computing device can determine information corresponding to a data structure and indicating delays associated with atrial leads, left ventricular (LV) leads, and right ventricular (RV) leads, based on one or more input variables. The computing device can determine multiple personalized characteristics based on the information corresponding to the data structure. The computing device can receive multiple second sets of electrical measurements from multiple measuring electrodes, based on the multiple personalized characteristics, indicating a second electrical signal applied to the patient's heart. The computing device can use a first set of electrical measurements (e.g., raw measurements) and the multiple second sets of electrical measurements to determine a cardiac resynchronization index (CRI) value. The computing device can generate a graphical representation based on the populated data structure and display the graphical representation.

The invention relates to an intrusive foldable left ventricle auxiliary device, the near end of a driving shaft is connected with a motor, the far end of the driving shaft is connected with a pump head assembly, and the pump head assembly comprises a foldable impeller driven by the driving shaft and an expandable support covering the periphery of the foldable impeller; the expandable stent is covered with a blood flow flexible film, a blood inlet is formed in the far end of the blood flow flexible film, and at least one blood outlet is formed in the near end area of the blood flow flexible film; the blood flow flexible membrane comprises a first channel, an expansion section and a second channel. When blood passes through the expansion section, the blood flow speed is reduced, the flow distribution is uniform, and the shearing force borne by the blood is directly reduced, so that the hemolysis risk is remarkably reduced from the source; meanwhile, blood flow is more stable, turbulent flow and flow stagnation areas are reduced, and the thrombosis risk is reduced; the near-end edge of the expansion section is located on the far side of the near-end edge of the expandable stent, after blood is decelerated, damage caused by impacting the inner wall of the stent is reduced, and hemolysis is further reduced.

The invention discloses a myocardial amyloidosis quantitative analysis method based on SPECT imaging and related equipment, and relates to the field of wisdom medical device.The method comprises the steps that firstly, three-dimensional SPECT original data of N time phases of a target patient in the cardiac cycle are collected, a mu graph is generated based on low-dose CT for registration and attenuation correction, and a dynamic image is reconstructed; and then an MR structure sequence under synchronous electrocardio gating is obtained, and SPECT and MR space standardization and partial volume effect correction processing are completed. And unifying the cardiac cycle image form through affine and nonlinear transformation, and generating a high-quality enhanced SPECT image. Finally, radioactive counting information is extracted on the basis of three-dimensional segmentation, multiple myocardial quantitative indexes are calculated, comprehensive analysis of myocardial functions is achieved in combination with left ventricular functional parameters, and accurate image support is provided for non-invasive diagnosis and curative effect evaluation of myocardial amyloidosis.

Provided is a health monitoring device that extracts, in particular, an apical beat component from a trunk acoustic pulse wave and thus is also usable in the medical field. The health monitoring device (1000) of the present invention analyzes a trunk acoustic pulse wave to estimate the health condition of a person using a correlation of an indicator relating to a left ventricular pressure waveform which indicates the behavior of the heart, with a vibration frequency of a frequency component stemming from an apical beat, a diastolic time interval in a cardiac cycle, or blood pressure. The former is input information and the latter is output information of the heart through which blood circulates, and thus comparing these two pieces of information makes it possible to know a health condition relating to the function of the heart more accurately than conventionally.